ArticleEMBO molecular medicine2020
Blocking interaction between SHP2 and PD-1 denotes a novel opportunity for developing PD-1 inhibitors.
Open access · goldAbstract read
In one paragraph
Article in EMBO molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 59 citations in OpenAlex.
- Photodynamic Therapy Combined with Anticancer Drug Therapy in the Treatment of Malignant Neoplasms.Cells · 2026Review
- Endogenous retroviruses and response to immune checkpoint inhibitors: mechanisms, clinical evidence, and therapeutic implications.Frontiers in immunology · 2026Review
- Repeated intravenous transplantation of human umbilical cord mesenchymal stem cells does not promote tumorigenesis in EGFR-mutated lung cancer mice.Stem cells translational medicine · 2025Article
- Blocking the PD-1 signal transduction by occupying the phosphorylated ITSM recognition site of SHP-2.Science China. Life sciences · 2025Article
- Current trends in sensitizing immune checkpoint inhibitors for cancer treatment.Molecular cancer · 2024Review
- Complex Roles ofAnnual review of cancer biology · 2024Article
- Anti-Tumor Potential of Post-Translational Modifications of PD-1.Current issues in molecular biology · 2024Review
- Small molecule agents for triple negative breast cancer: Current status and future prospects.Translational oncology · 2024Review
- Review
- Cellular interactions in tumor microenvironment during breast cancer progression: new frontiers and implications for novel therapeutics.Frontiers in immunology · 2024Review
- Advances in PD-1 signaling inhibition-based nano-delivery systems for tumor therapy.Journal of nanobiotechnology · 2023Review
- Tumor microenvironment signaling and therapeutics in cancer progression.Cancer communications (London, England) · 2023Review
- Human recombinant soluble PD1 can interference in T cells and Treg cells function in response to MDA-MB-231 cancer cell line.American journal of clinical and experimental immunology · 2023Article
- A comprehensive review of SHP2 and its role in cancer.Cellular oncology (Dordrecht, Netherlands) · 2022Review
- Small-Molecule PROTACs for Cancer Immunotherapy.Molecules (Basel, Switzerland) · 2022Review
- Targeting protein phosphatases for the treatment of inflammation-related diseases: From signaling to therapy.Signal transduction and targeted therapy · 2022Review
- SHP2 allosteric inhibitor TK-453 alleviates psoriasis-like skin inflammation in mice via inhibition of IL-23/Th17 axis.iScience · 2022Article
- Targeting SHP2 phosphatase in hematological malignancies.Expert opinion on therapeutic targets · 2022Review
- Combination Approaches to Target PD-1 Signaling in Cancer.Frontiers in immunology · 2022Review
- Targeting SHP2 sensitizes differentiated thyroid carcinoma to the MEK inhibitor.American journal of cancer research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 2 countries.
Zhenzhen Fan *MOE Key Laboratory of Tumor Molecular Biology and Key Laboratory of Functional Protein Research of Guangdong Higher Education Institutes, Institute of Life and Health Engineering, Jinan University, Guangzhou, China.
Yahui Tian *MOE Key Laboratory of Tumor Molecular Biology and Key Laboratory of Functional Protein Research of Guangdong Higher Education Institutes, Institute of Life and Health Engineering, Jinan University, Guangzhou, China.
Zhipeng ChenMOE Key Laboratory of Tumor Molecular Biology and Key Laboratory of Functional Protein Research of Guangdong Higher Education Institutes, Institute of Life and Health Engineering, Jinan University, Guangzhou, China.
Lu LiuMOE Key Laboratory of Tumor Molecular Biology and Key Laboratory of Functional Protein Research of Guangdong Higher Education Institutes, Institute of Life and Health Engineering, Jinan University, Guangzhou, China.
Qian ZhouMOE Key Laboratory of Tumor Molecular Biology and Key Laboratory of Functional Protein Research of Guangdong Higher Education Institutes, Institute of Life and Health Engineering, Jinan University, Guangzhou, China.
Jingjing HeSun Yat-Sen University Cancer Center, Guangzhou, China.
James ColemanBiomedical Research Centre, Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, UK.ORCID 0000-0001-7430-2587
Changjiang DongBiomedical Research Centre, Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, UK.ORCID 0000-0002-7020-5648
Nan LiMOE Key Laboratory of Tumor Molecular Biology and Key Laboratory of Functional Protein Research of Guangdong Higher Education Institutes, Institute of Life and Health Engineering, Jinan University, Guangzhou, China.
Junqi HuangMOE Key Laboratory of Tumor Molecular Biology and Key Laboratory of Functional Protein Research of Guangdong Higher Education Institutes, Institute of Life and Health Engineering, Jinan University, Guangzhou, China.
Chenqi XuState Key Laboratory of Molecular Biology, Shanghai Science Research Center, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China.
Zhimin ZhangSchool of Pharmacy, Jinan University, Guangzhou, China.
Song GaoSun Yat-Sen University Cancer Center, Guangzhou, China.ORCID 0000-0001-7427-6681
Penghui ZhouSun Yat-Sen University Cancer Center, Guangzhou, China.ORCID 0000-0003-0519-461X
Ke DingSchool of Pharmacy, Jinan University, Guangzhou, China.ORCID 0000-0001-9016-812X
Liang ChenMOE Key Laboratory of Tumor Molecular Biology and Key Laboratory of Functional Protein Research of Guangdong Higher Education Institutes, Institute of Life and Health Engineering, Jinan University, Guangzhou, China.ORCID 0000-0001-7300-6604
Jinan University · CNSun Yat-sen University · CNUniversity of East Anglia · GBCenter for Excellence in Molecular Cell Science · CN
Funding
Fundamental Research Funds for the Central Universities 21618326Guangzhou Research Project of Science and Technology for Citizen Health 201803010124NSF|Foundation for Innovative Research Groups of the National Natural Science Foundation of China 31701174NSF|Foundation for Innovative Research Groups of the National Natural Science Foundation of China 31800723NSF|Foundation for Innovative Research Groups of the National Natural Science Foundation of China 81672309NSF|Foundation for Innovative Research Groups of the National Natural Science Foundation of China 81972778Science and Technology Program of Guangdong 2017B020227001
Abstract
Small molecular PD-1 inhibitors are lacking in current immuno-oncology clinic. PD-1/PD-L1 antibody inhibitors currently approved for clinical usage block interaction between PD-L1 and PD-1 to enhance cytotoxicity of CD8
Indexed as
Antineoplastic AgentsProgrammed Cell Death 1 ReceptorAnimalsB7-H1 AntigenCD8-Positive T-LymphocytesHumansImmune Checkpoint InhibitorsMiceProtein Tyrosine Phosphatase, Non-Receptor Type 11T-Lymphocytes, CytotoxicAntineoplastic AgentsB7-H1 AntigenImmune Checkpoint InhibitorsPDCD1 protein, humanPdcd1 protein, mouseProgrammed Cell Death 1 ReceptorProtein Tyrosine Phosphatase, Non-Receptor Type 11PTPN11 protein, humanPtpn11 protein, mouseimmunotherapymethylene bluePD-1small molecular inhibitortransgenic mouse model
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.